March 24, 2020 / 12:32 AM / 7 days ago

BRIEF-Spagopix Says Phase I Study To Next Dose Level And Expansion To Additional Site

March 23 (Reuters) - Spago Nanomedical AB (publ):

* SPAGOPIX PHASE I STUDY TO NEXT DOSE LEVEL AND EXPANSION TO ADDITIONAL SITE

* SPAGO NANOMEDICAL AB (PUBL) - DATA FROM FIRST DOSE GROUP IN PHASE I TRIAL SHOW THAT SN132D IS WELL TOLERATED

* SPAGO NANOMEDICAL AB (PUBL) - ISRC FURTHER CONCLUDE THAT SN132D DOSE SHOULD BE INCREASED IN ORDER TO OPTIMIZE CONTRAST ENHANCEMENT OF TUMORS

* SPAGO NANOMEDICAL AB (PUBL) - DECIDED TO EXPAND SN132D STUDY TO ADDITIONAL BREAST CANCER CENTER, SAHLGRENSKA UNIVERSITY HOSPITAL Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below